NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (“ 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

The Centers for Disease Control and Prevention has issued updated advice on the COVID-19 vaccine days after Health and Human Services Secretary Robert F. Kennedy Jr said the agency would no longer ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

WEKA, the AI-native data platform company, announced that it has been recognized as a Customers' Choice in the 2025 Gartner®?Peer Insightstm?Voice of the Customer: File and Object Storage Platforms ...

Harvard University is battling the Trump administration’s attempt to block it from enrolling international students, citing ...

In a landmark discovery, researchers have unveiled the highly dynamic and adaptable architecture of the mammalian pyruvate ...

Cofactor Genomics announced the latest validation results for OncoPrism ®, Cofactor's breakthrough RNA-based diagnostic approach at the RNA Society's 30th Annual Meeting. The talk, presented by Dr.

The global Phenylketonuria (PKU) Treatment is undergoing a strategic transformation, driven by novel drug candidates and a more targeted understanding of unmet clinical needs. With a global prevalence ...

Monica Crowley’s rise from a political science graduate at Colgate University to the US ambassador and chief of protocol ...

NCR Atleos Corporation ("Atleos"), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced it was ranked #12 in Newsweek's prestigious ...

Demand Spring delivers AI and automation services that fuel innovation, productivity and growth for CMOs. Over the past few ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 ...